These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24237017)

  • 21. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM; Kesselheim AS
    N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
    [No Abstract]   [Full Text] [Related]  

  • 22. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 23. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 24. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways.
    Druedahl LC; Almarsdóttir AB; Kälvemark Sporrong S; De Bruin ML; Hoogland H; Minssen T; van de Weert M; Kesselheim AS; Sarpatwari A
    Nat Biotechnol; 2020 Nov; 38(11):1253-1256. PubMed ID: 33144720
    [No Abstract]   [Full Text] [Related]  

  • 25. Navigating the maze of IP/regulatory rights in the EU: the complex interaction between the SPC and Pediatric Regulations.
    Manley MI; Vickers M
    Pharm Pat Anal; 2013 Mar; 2(2):161-4. PubMed ID: 24237019
    [No Abstract]   [Full Text] [Related]  

  • 26. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 27. Applying a gaming approach to IP strategy.
    Gasnier A; Vandamme L
    IDrugs; 2010 Feb; 13(2):97-102. PubMed ID: 20127561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 29. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intellectual property. U.S. patent office reworks unpopular policy.
    Servick K
    Science; 2015 Jan; 347(6218):113. PubMed ID: 25573998
    [No Abstract]   [Full Text] [Related]  

  • 31. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 32. Intellectual property. U.S. patent reform begins long journey through Congress.
    Kintisch E
    Science; 2005 Jun; 308(5729):1725-6. PubMed ID: 15961638
    [No Abstract]   [Full Text] [Related]  

  • 33. China tightens IP protection, but concerns linger.
    Jia H
    Nat Biotechnol; 2009 Sep; 27(9):787-8. PubMed ID: 19741619
    [No Abstract]   [Full Text] [Related]  

  • 34. Legal developments and practical implications of gene patenting on targeted drug discovery and development.
    Klein RD
    Clin Pharmacol Ther; 2010 Jun; 87(6):633-5. PubMed ID: 20485317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling.
    Simon JH; Claassen E; Correa CE; Osterhaus AD
    Bull World Health Organ; 2005 Sep; 83(9):707-10. PubMed ID: 16211163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectively managing an IP portfolio? Not an easy task.
    Pontremoli G
    Pharm Pat Anal; 2020 Jan; 9(1):7-8. PubMed ID: 32008443
    [No Abstract]   [Full Text] [Related]  

  • 37. [Germany joins the Nagoya Protocol: campaign against biopiracy].
    Pflege Z; 2016 May; 69(5):256. PubMed ID: 27504518
    [No Abstract]   [Full Text] [Related]  

  • 38. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 40. Patent watch: Microscale implantable drug delivery systems: emerging IP strategies.
    Daukss D; Statler K
    Nat Rev Drug Discov; 2016 Nov; 15(11):740-741. PubMed ID: 27739511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.